Company Information
Company Profile
Cash Flow Statement
Profit & Loss
Financial Position
Financial Ratio
Industry 制造业
Company Introduction 福元医药2022年6月30日上市，股票代码601089。公司主要从事药品制剂及医疗器械的研发、生产和销售，以“专注医药领域，共创健康人生”为使命，致力于打造研发、生产、销售三位一体的核心竞争优势，持续打造规模化产品群，形成“领域、品种、技术”组合优势的丰富产品线，构建从原料到药品完整周期的产业价值链。公司已入选北京医药产业跨越发展工程G20企业，荣列中国化药研发实力百强榜，获得行业内外的广泛认可。 公司确立了临床急需、仿创结合的研发战略，已对化学创新药等新领域进行布局，公司产品品类丰富，药品制剂主要涵盖心血管系统类、慢性肾病类、皮肤病类、消化系统类、糖尿病类、精神神经系统类、妇科类等多个产品细分领域；医疗器械业务以临床护理产品为主。 公司建立了全国性销售网络，组建了专业、高效的销售队伍进行市场深耕，拥有自身特色的多种营销模式，销售网络的全面性和销售团队的专业性为公司销售规模稳定增长提供了保障。
Main Business 主要从事药品及医疗器械研发、生产和销售
Legal Representative 黄河
Top Executives
董事长：黄河
董事：黄河,崔欣荣,石观群,胡柏藩,胡少羿
独立董事：李立东,刘书锦,郑晓东,陈劲
Top 5 Shareholder
Shareholder name Nature Holding Date
新和成控股集团有限公司限售股36.73%30/09/2024
新昌勤进投资有限公司限售股20.49%30/09/2024
北京华康泰丰科技有限责任公司流通A股14.63%30/09/2024
香港中央结算有限公司流通A股1.97%30/09/2024
宣城人和投资合伙企业（有限合伙）流通A股0.79%30/09/2024
Company Secretary 李永
Solicitors 浙江天册律师事务所
Auditors 天健会计师事务所（特殊普通合伙）
Tel No 010-59603941
Fax No 010-59603942
Website www.foyou.com.cn
Email ir@foyou.com.cn;Kaiwei.zheng@foyou.com.cn
Company Address
Register: 北京市通州区通州工业开发区广源东街8号
Office: 北京市通州区通州工业开发区广源东街8号
Listing Date 30/06/2022
Shares Capital
Shares Capital: 480,000,000
Total A Share: 480,000,000
Listed A Share: 205,346,413
Non-tradable A Share: 274,653,587
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 1.020
DPS(RMB)* ¥ 0.500
NBV Per Share(RMB)* ¥ 7.226
Market Capitalization(RMB) 3.224B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.